Cancer research:

PROGRESS AND CHALLENGES

Oncology is at the forefront of the precision medicine revolution, helping to deliver impressive gains in patient survival.

The list of actionable cancer drivers is growing at a remarkable pace, emphasizing huge progress against major drug targets such as EGFR, ALK, BCR-ABL, and more recently K-RAS. Although, even for successful cancer drugs - resistance is common and much remains to be done.

TRC is the perfect partner to help you develop the more selective, lower-toxicity drugs that are required to truly expedite therapeutic success. Our cancer research chemicals portfolio contains more than 11,000 products, with an extensive ready-to-ship catalogue including:

- APIs
- Drug derivatives
- Bioactive molecules
- Stable isotope labelled compounds

All products are delivered with a complete analytical data package as per request, including:

- **Full spectroscopic analysis - including NMR, HPLC, MS and elemental analysis**
- **COAs - purity and testing information**
- **Additional analyses on demand - such as KF and TGA**

Our large and novel range of highly characterised research chemicals can support you from early-stage research to drug discovery and toxicology.

View our cancer research catalogue here

Need to discuss a specific project? We specialise in multi-step and complex custom synthesis.

Talk to our experts today!

SCAN ME

Contact us

T | +1 (416) 665-9696 I US & Canada: +1 (800) 727-9240

E | info.trc@lgcgroup.com

W I www.lgcstandards.com/TRC

TRC Research areas and targets

Boost your cancer research with TRC

With more than 3,900 ready-to-ship cancer research chemicals - molecules, drug derivatives, impurities, metabolites, stable isotope labelled compounds, and more.

Need to discuss a specific project? We specialise in multi-step and complex custom synthesis.

Talk to our experts today!

Apoptosis	▪ Apotosis inducers ▪ Apotosis inhibitors ▪ ASK1 ▪ BCL-2 family	▪ Calpains ▪ Caspases ▪ p53
Angiogenesis	▪ EGF receptors ▪ PDGF receptors	▪ VEGF receptors ▪ HIF
Tumour microenvironment	▪ Chemokine receptors ▪ Cytokine receptors ▪ Cytokines	▪ MMPs ▪ TGF-β receptors ▪ Toll like receptors
Cell cycle	▪ CDKs ▪ Aurora kinases ▪ CD25 phosphatases ▪ Cell cycle inhibitors	▪ Checkpoint control kinases ▪ p53 ▪ Poly (ADP-ribose) polymerase
Epigenetics	▪ Bromodomains ▪ DNA methyltransferases ▪ Histone acetyltransferases ▪ Histone deacetylase	▪ Histone demethylase ▪ Protein tyrosine phosphatases ▪ Poly (ADP-ribose) polymerase
Cancer metabolism	▪ ATP citrate lyase ▪ Carbonic anhydrase ▪ Difolate reductyase ▪ Fatty acid synthase	▪ Glucose transporters ▪ Hexokinases ▪ Oxidative phosphorylation ▪ HMG-CoA reductase
Cancer immunology	▪ Adenosine A2A / A2B ▪ Chemokine receptors ▪ Immune checkpoints ▪ JAK family ▪ PI3K ▪ Prostanoid receptors	▪ Purinergic P2X /Y receptors ▪ STATs ▪ Sting signalling ▪ Toll like receptors ▪ TGF-β receptors
Receptor tyrosine	▪ ALK ▪ CSF1 receptors ▪ EGF receptors ▪ FGFR receptors ▪ FLT3 receptors ▪ HER2 receptors ▪ KIT receptors	▪ MET receptors ▪ PDGF receptors ▪ RET receptors ▪ ROS1 receptors ▪ VEGF receptors ▪ Insulin receptors ▪ IGF1 receptors
Non-receptor tyrosine kinases	▪ BTK ▪ JAK1/2 ▪ BCR-ABL	▪ SRC ▪ ABL ▪ FAK
Ser / Thr kinases	▪ AKT ▪ ATM ▪ B-RAF ▪ CDK	▪ PKC ▪ MAPK ▪ CAMK ▪ MEK
Lipid kinases	▪ PI3K	

Contact us

T | +1 (416) 665-9696 I US & Canada: +1 (800) 727-9240

E | info.trc@lgcgroup.com

W I www.lgcstandards.com/TRC

View our cancer research catalogue here

SCAN ME